Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
Purpose: The IMpassion130 trial demonstrated the efficacy of adding atezolizumab to paclitaxel for advanced or metastatic triple-negative breast cancer (TNBC). The current study evaluated the cost-effectiveness of adding atezolizumab to nab-paclitaxel for TNBC from the perspective of Chinese health...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-10-01
|
| Series: | Frontiers in Public Health |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2021.756899/full |
| _version_ | 1818925930584735744 |
|---|---|
| author | Xiaoyan Liu Xiaoyan Liu Yitian Lang Yahui Liao Yizhun Zhu |
| author_facet | Xiaoyan Liu Xiaoyan Liu Yitian Lang Yahui Liao Yizhun Zhu |
| author_sort | Xiaoyan Liu |
| collection | DOAJ |
| description | Purpose: The IMpassion130 trial demonstrated the efficacy of adding atezolizumab to paclitaxel for advanced or metastatic triple-negative breast cancer (TNBC). The current study evaluated the cost-effectiveness of adding atezolizumab to nab-paclitaxel for TNBC from the perspective of Chinese health sector.Methods: A partitioned survival model was implemented for patients with TNBC. The survival data were derived from IMpassion130 trial. Direct costs and utility values were collected from the Chinese Drug Bidding Database and published literatures. The primary analysis outcomes were quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs). Sensitivity analyses were performed to observe model stability.Results: In the base-case analysis, the ICER of atezolizumab plus nab-paclitaxel vs. nab-paclitaxel is respectively, $176,056/QALY, $118,146/QALY, and $323,077/QALY in the ITT, PD-L1(+) and PD-L1(–) group.Conclusion: Adding atezolizumab to nab-paclitaxel could improve survival time significantly in the PD-L1-positive group, but it is not a cost-effective strategy compared to nab-paclitaxel monotherapy for Chinese patients with advanced or metastatic triple-negative breast cancer in the current economic context of China. |
| first_indexed | 2024-12-20T02:49:03Z |
| format | Article |
| id | doaj.art-ea089e60e5b94fbea5de06396310417a |
| institution | Directory Open Access Journal |
| issn | 2296-2565 |
| language | English |
| last_indexed | 2024-12-20T02:49:03Z |
| publishDate | 2021-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Public Health |
| spelling | doaj.art-ea089e60e5b94fbea5de06396310417a2022-12-21T19:56:06ZengFrontiers Media S.A.Frontiers in Public Health2296-25652021-10-01910.3389/fpubh.2021.756899756899Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness AnalysisXiaoyan Liu0Xiaoyan Liu1Yitian Lang2Yahui Liao3Yizhun Zhu4Department of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaState Key Laboratory of Quality Research in Chinese Medicine, School of Pharmacy, Macau University of Science and Technology, Taipa, Macau SAR, ChinaDepartment of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaState Key Laboratory of Quality Research in Chinese Medicine, School of Pharmacy, Macau University of Science and Technology, Taipa, Macau SAR, ChinaPurpose: The IMpassion130 trial demonstrated the efficacy of adding atezolizumab to paclitaxel for advanced or metastatic triple-negative breast cancer (TNBC). The current study evaluated the cost-effectiveness of adding atezolizumab to nab-paclitaxel for TNBC from the perspective of Chinese health sector.Methods: A partitioned survival model was implemented for patients with TNBC. The survival data were derived from IMpassion130 trial. Direct costs and utility values were collected from the Chinese Drug Bidding Database and published literatures. The primary analysis outcomes were quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs). Sensitivity analyses were performed to observe model stability.Results: In the base-case analysis, the ICER of atezolizumab plus nab-paclitaxel vs. nab-paclitaxel is respectively, $176,056/QALY, $118,146/QALY, and $323,077/QALY in the ITT, PD-L1(+) and PD-L1(–) group.Conclusion: Adding atezolizumab to nab-paclitaxel could improve survival time significantly in the PD-L1-positive group, but it is not a cost-effective strategy compared to nab-paclitaxel monotherapy for Chinese patients with advanced or metastatic triple-negative breast cancer in the current economic context of China.https://www.frontiersin.org/articles/10.3389/fpubh.2021.756899/fullatezolizumabcost-effectivenesspartitioned survival modeltriple-negative breast cancerthe perspective of China |
| spellingShingle | Xiaoyan Liu Xiaoyan Liu Yitian Lang Yahui Liao Yizhun Zhu Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis Frontiers in Public Health atezolizumab cost-effectiveness partitioned survival model triple-negative breast cancer the perspective of China |
| title | Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis |
| title_full | Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis |
| title_fullStr | Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis |
| title_full_unstemmed | Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis |
| title_short | Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis |
| title_sort | atezolizumab plus chemotherapy vs chemotherapy in advanced or metastatic triple negative breast cancer a cost effectiveness analysis |
| topic | atezolizumab cost-effectiveness partitioned survival model triple-negative breast cancer the perspective of China |
| url | https://www.frontiersin.org/articles/10.3389/fpubh.2021.756899/full |
| work_keys_str_mv | AT xiaoyanliu atezolizumabpluschemotherapyvschemotherapyinadvancedormetastatictriplenegativebreastcanceracosteffectivenessanalysis AT xiaoyanliu atezolizumabpluschemotherapyvschemotherapyinadvancedormetastatictriplenegativebreastcanceracosteffectivenessanalysis AT yitianlang atezolizumabpluschemotherapyvschemotherapyinadvancedormetastatictriplenegativebreastcanceracosteffectivenessanalysis AT yahuiliao atezolizumabpluschemotherapyvschemotherapyinadvancedormetastatictriplenegativebreastcanceracosteffectivenessanalysis AT yizhunzhu atezolizumabpluschemotherapyvschemotherapyinadvancedormetastatictriplenegativebreastcanceracosteffectivenessanalysis |